|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Alzheimer Disease Therapeutics Market Report further provides information about Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD. Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipeline.
Other Key Points in Report:
The AD market has a lack of therapeutic options.
-Which classes of drug dominate the market?
-What newly approved therapies have entered the market?
-How do the leading marketed therapies compare clinically?
-How will the new therapies be positioned in the treatment of AD?
-How have selected late-stage pipeline therapies performed in clinical trials?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.
-Which molecular targets appear most frequently in the pipeline?
AD clinical trials have an overall attrition rate of 94%.
-What are the failure rates for individual Phases of clinical development?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170045/buying
Table of Content: An Overview
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 9
2.3 Symptoms 10
2.4 Etiology 12
2.5 Pathophysiology 12
2.6 Disease Stages 13
2.7 Diagnosis 14
2.8 Prognosis 17
2.9 Treatment 18
2.9.1 Treatment Algorithm 18
2.9.2 Mild-to-Moderate AD 20
2.9.3 Moderate-to-Severe AD 21
3 Marketed Products 22
3.1 Aricept (donepezil)-Eisai 22
3.2 Exelon (rivastigimine)-Novartis 22
3.3 Razadyne (galanatamine)-Janssen 23
3.4 Namenda/Ebixa/Axura/Abixa (memantine), Merz Pharma/Lundbeck/Forest/Daiichi Sankyo 23
3.5 Cognex (tacrine)-Shiniogi 24
3.6 Namzaric (memantine ER + donepezil), Actavis-Adamas 24
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170045/discount
4 Heat Map-Marketed Products Overview 25
5 Pipeline Product Developments 26
5.1 The Pipeline Development Landscape 26
5.2 Mechanisms of Action in the Pipeline 27
5.3 Clinical Trials 31
5.3.1 Failure Rate 31
5.3.2 Clinical Trial Duration 32
5.3.3 Clinical Trial Size 34
5.3.4 Competitive Clinical Trials Metric Analysis 38
5.4 Promising Pipeline Molecules 39
5.4.1 MK-8931-Merck & Co. 39
5.4.2 LMTX (methylthioninium chloride)-TauRX Therapeutics 40
5.4.3 AZD3293-AstraZeneca 41
5.4.4 AB1010-AB Science 42
5.4.5 BIIB037-Biogen 43
5.4.6 TP488-vTv Therapeutics 44
5.4.7 EVP-6124-FORUM Pharmaceuticals 45
5.4.8 LuAE58054-Lundbeck 46
5.4.9 Gantenerumab (R-1540/RG-1450)-Roche 47
6 Heat Map-Pipeline Products Overview 50
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170045/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
